Periodic Reporting for period 1 - CP2 (CP2 is a project to develop a new wrist placement technology that can detect anomalies with both the Cardio and Vascular systems simultaneously.)
Periodo di rendicontazione: 2014-10-01 al 2015-03-31
The Phase 1 CP2 project has looked at the feasibility of creating a step change in the screening of people for both cardio and vascular issues through a single device, building on the achievements of our already established hand placement medical device platform. The six month study looked to seek advice from a wide range of parties. With direct input from over 500 patients and 25 GPs, the CP2 project has shown that there is a real desire to move away from the incumbent unreliable and uncomfortable inflatable-cuff technologies, to a system that can provide higher fidelity time series blood pressure readings and high fidelity cardiac rhythm analysis simultaneously. By combining the acquisition of Blood Pressure and ECG measurements, it is anticipated that the CP2 device will allow for the fusion of Cardio (ECG) and Vascular (blood pressure) data in order to provide further cardiovascular performance markers, as well as eventually being used to identify other underlying physiological conditions such as Aortic Stenosis and Peripheral Arterial Disease. Using CP2’s unique patient interface, there is real potential to acquire higher fidelity and more useful data from subjects in a much more patient friendly and acceptable fashion. Keeping the subjects’ clothes on whilst taking such readings makes for a system that has obvious special significance with religions, such as Islam.
The works performed included a review of the proposed conceptual product with our Primary Care Clinical partners, culminating in receiving the reviews of 25 Clinicians and a patient cohort of 500. An initial design review was conducted which delivered a potential design solution. A market study was conducted that identified the nearest competitive product and confirmed that a route to market was available in the UK and confirmed the proposed pricing point was acceptable. An IP review was conducted to confirm Freedom to Operate along with an Academic review looking at the state of the art of the possible. Finally a Business Plan was developed to move CP2 forward.
The CP2 device combines several innovations into a single device that will be quick and convenient to use. It addresses two key CV risk parameters that carry a significant clinical and cost burden and are normally cost modelled separately. Given its wide application and low cost, this device will offer a cost effective solution to the NHS and other countries with regards proactive screening for Cardio Vascular performance.